Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolong ejaculation.
Popular Articles

Intraoperative Radioguidance With A Portable Gamma Camera: New Technique For Laparoscopic Sentinel Node Localisation In Urological Malignancies
UroToday.com - Our first results of sentinel node mapping with intraoperative radioguidance in urological tumors are described in our abstract. We selected this movie to show the whole imaging procedure. In a patient with prostate cancer, the radiopharmaceutical is injected in 4 depots into the prostate. After tracer administration, planar lymphoscintigraphy is performed after 15 minutes and in 2 hours is followed by a SPECT/CT. After fusion of corresponding SPECT and CT slices, the two-dimensional fusion images show the location of the sentinel nodes.
generic viagra
Test For Strep Bacteria In Pregnant Women Misses More Cases Than Expected, Study Shows
A federal recommendation that all pregnant women undergo testing for Group B strep bacteria has helped increase the number of screenings but also has produced a high level of false negatives, according to a study published Thursday in the New England Journal of Medicine, the AP/Newark Star-Ledger reports. Group B strep is a common bacteria in the intestines or lower genital tract. Although it poses no harm to most adults, during delivery it can be spread to infants, who can develop blood infections, pneumonia, meningitis, mental retardation, hearing and vision loss, or death. Problems occur in fewer than one in 3,000 births, but the Centers for Disease Control and Prevention in 2002 issued a recommendation that all pregnant women be tested because of the potential for serious complications. The study is the first research to examine the screening program. The researchers examined data on Group B strep cases in 10 states, finding that 250 infants out of nearly 7,700 were born with the infection. They compared the results with a similar study that was conducted before the CDC recommendations were in place, finding that the screening rate rose from 48% to 85% of pregnant women. The study also found that infant infections from Group B strep declined by 27%.Researchers predicted there would be between 44 and 86 false negatives in full-term infants, based on data from previous studies. However, their results showed about 60% of infected infants -- 116 cases -- were born to women who had tested negative for Group B strep. Researchers noted that the timing of a Group B test might play a role because the infection can come quickly, and tests could have been performed before the bacteria appeared. CDC recommends that pregnant women be screened between 35 and 37 weeks" gestation. CDC researcher Stephanie Schrag, who co-authored the study, said, "Maybe it was a true negative test, and the mother later became colonized" with the bacteria before delivery (Stobbe, AP/Newark Star-Ledger, 6/17).
News of the day
New Diagnostic Method For Gout: Dual Energy Computed Tomography Instead Of Joint Aspiration
The most reliable method of diagnosing gout is to aspirate the joint in order to obtain fluid
Diagnostics

PBS Listing Of Antifungal Suspension Welcomed By Paediatricians

General Practitioners and specialists will be able to prescribe VFEND® (voriconazole) oral suspension for immuno-suppressed adolescents and children following its listing on the Pharmaceutical Benefits Scheme (PBS) from 1 August 2009. VFEND® is a broad-spectrum antifungal agent for the treatment and maintenance therapy of definite or probable invasive aspergillosis, including disseminated disease and aspergillosis which has been unresponsive to other therapies.1,2 Invasive aspergillosis is an important cause of morbidity and mortality in transplant recipients and immuno-compromised patients with haematological malignancies.Âð Dr Anne Thomas, Associate Medical Director, Specialty Care, Pfizer believes: "The listing of VFEND® oral suspension provides easier access to medication in a form suitable to children, while easing pressure off hospitals as the only of this medicine." Associate Professor David Ellis, Head of Mycology, Women"s and Children"s Hospital agrees stating the "PBS listing of voriconazole oral suspension will provide further flexibility in patient care, an important component in the successful management of invasive fungal infections; especially for pediatric and other patients who may have difficulty swallowing tablets". Previously, this antifungal - a first-line therapy also used for scedosporium or fusarium fungal infections, and a second line therapy for both candida and other serious invasive mycosis - was only available through hospitals.1,2 Professor Peter Shaw, Head of Bone Marrow Transplant Unit, The Children"s Hospital Westmead explains that VFEND® Suspension has been much anticipated by paediatricians. "Voriconazole is a standard drug used in many of our patients undergoing Blood and Marrow Transplant. These patients are all children undergoing unrelated or mismatched procedures and often come to BMT with pre-existing invasive fungal infection. Our ability to give them multiple medications in the early months post BMT, as well as adequate nutrition and fluid, is often hampered by the tolerability of all the drugs. We have extensive experience with the use of Voriconazole suspension and find it well tolerated and can achieve acceptable blood levels in most patients. These patients often require maintenance treatment for several months and the ability to give younger out-patients Voriconazole suspension certainly makes it easier to manage them" said Professor Shaw. VFEND® is also a treatment option for other life-threatening fungal infections such as cryptococcosis.2 Additionally, VFEND® is used to treat serious candida infections such as invasive candidiasis and candidaemia - increasingly common, costly and potentially fatal yeast infections, particularly affecting the immuno-compromised and critically ill.1,2 The most common side effects of VFEND® are visual disturbances, fever, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema and abdominal pain2. The severity is generally mild to moderate. VFEND® is contraindicated with the simultaneous use of cisapride, pimozide, quinidine, rifampicin, carbamazepine, long-acting barbiturates, ergot alkaloids, sirolimus and St John"s Wort. It should also be used with caution in patients with hypersensitivity to azoles and proarrhythmic conditions2. Prior to prescribing, please review full Product Information for VFEND®, is available at http://www.pfizer.com.au. VFEND® is available in tablets, oral suspension and intravenous injections and is PBS listed for adults as well. The most recent PBS listing is specifically for oral suspension (40mg/mL 70mL) for adolescents and children aged 2 and over. VFEND® Tablets (50mg or 200mg) are also available on the PBS but VFEND® intravenous injections are still only accessible through hospitals. Health professionals with questions about VFEND® should contact Pfizer Medical Affairs on 1800 675 229. References Âð Thursky KA, Playford EG, Seymour JF et al. Intern Med J 2008; 38(6b): 496-520 ² VFEND® (voriconazole) Product Information. Pfizer Australia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009